Clinical Research Directory

Inclusion Criteria: * Patient has diagnosed heart failure for ≥90 days and current symptoms compatible with NYHA class II-III (according to most recent assessment) * At least ONE of the following: At least one documented admission with a primary diagnosis of worsening heart failure within last 12 months prior to enrollment; OR Unscheduled outpatient visit with increase of oral loop diuretics (more than 2-fold) or IV diuretic or ultrafiltration therapy for acute WHF within last 6 months prior to enrollment; OR elevated NT-proBNP/BNP values within last 3 months prior to enrollment i.e.: If LVEF \>50% --\> Patients in SR: \>450 / \>150 pg/ml; Patients with AF present: \>900 / \>300 pg/ml If LVEF \<50% --\> Patients in SR: \>900 / \>300 pg/ml; Patients with AF present: \>1800 / \>450 pg/ml * Ability to understand the nature of the study * Willingness to provide written informed consent * Ability and willingness to perform follow-up visits at the study site and via phone * Ability and willingness to use the CardioMessenger and acceptance of the BIOTRONIK Home Monitoring concept Exclusion Criteria: * Implanted with pacemaker, ICD or CRT device or ICM * Class I indication for a pacemaker, ICD or CRT according to current guidelines. * Permanent or long-standing persistent AF * Stroke, MI or PCI/CABG within 3 months prior to enrollment * Patient is on chronic renal or peritoneal dialysis * Patient has complex adult congenital heart disease * Patient has active cancer involving chemotherapy, immunotherapy or radiation therapy * Patient life expectancy is less than 1 year * Age \<18 years * Patient is participating in any other device or drug trial that may interfere with the treatment or protocol of this study or may significantly affect the study outcomes